M&A Deal Summary |
|
|---|---|
| Date | 2012-05-01 |
| Target | PreCision Dermatology |
| Sector | Medical Products |
| Buyer(s) | Triax Pharmaceuticals |
| Sellers(s) | EW Healthcare Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 85M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2004 |
| Sector | Healthcare Services |
Triax Pharmaceuticals, LLC a specialty pharmaceutical company, engages in the development, sale, and marketing of dermatological products in the United States.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Medical Products) | 1 of 1 |
| Type (Add-on Acquisition) | 1 of 1 |
| State (Rhode Island) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2012) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-02-03 |
PreCision Dermatology
Cumberland, Rhode Island, United States PreCision Dermatology, Inc. is a specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products. Our mission is to develop innovative skincare therapies with proven clinical performance that patients prefer and physicians are confident to prescribe. |
Sell | $475M |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.
| DEAL STATS | # |
|---|---|
| Overall | 29 of 53 |
| Sector (Medical Products) | 15 of 24 |
| Type (Add-on Acquisition) | 19 of 34 |
| State (Rhode Island) | 1 of 1 |
| Country (United States) | 25 of 46 |
| Year (2012) | 2 of 3 |
| Size (of disclosed) | 19 of 22 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-04-30 |
EUSA Pharma
Langhorne, Pennsylvania, United States EUSA Pharma is a trans-Atlantic specialty pharmaceutical company focused on oncology and critical care. EUSA intends to build a portfolio of products that are on the market or in late-stage clinical trials through acquisitions and in-licensing. The company has a sales and marketing organization and commercial infrastructure in the US and all major European countries. |
Sell | $680M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-05-07 |
Bioventus
Durham, North Carolina, United States Bioventus provides clinical and cost-effective therapies and diagnostics to help patients regain active lifestyles. The company's innovative products include bone stimulation devices and osteoarthritis joint fluid therapies. Bioventus was incorporated in 2011 and is based in Durham, North Carolina. |
Buy | - |
